Chimeric antigen receptor-engineered T cells as oncolytic virus carriers

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Adoptive transfer of engineered T cells is effective against hematological cancers but limited for solid tumors.
• Oncolytic viruses (OVs) can lyse tumor cells and cause vascular shutdown, but require high doses for systemic efficacy.
• Delivering OVs via T cells could overcome systemic delivery challenges and enhance tumor targeting.

Purpose of the Study:

• To investigate the feasibility and efficacy of using engineered T cells to deliver oncolytic viruses (OVs) for cancer therapy.
• To determine if loading T cells with OVs affects their receptor expression or function.
• To assess the impact of this combination therapy on tumor cell lysis and overall tumoricidal activity.

Main Methods:

• Chimeric antigen receptor-engineered T cells (murine and human) were loaded with low doses of OVs (RNA or DNA viruses).
• T cell receptor expression and function were assessed post-loading.
• The ability of engineered T cells to deposit virus onto tumor targets and enhance tumoricidal activity was evaluated.

Main Results:

• Loading engineered T cells with OVs did not impair T cell receptor expression or function.
• Engineered T cells successfully delivered OVs to various tumor targets.
• The combination of engineered T cells and OVs demonstrated enhanced tumoricidal activity in both murine and human models.

Conclusions:

• Loading engineered T cells with OVs is a viable strategy for enhancing cancer therapy.
• This novel combination approach shows broad applicability for treating solid tumors.
• Engineered T cell-mediated OV delivery represents a promising new avenue in cancer immunotherapy.